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Resection or radiofrequency ablation of colorectal liver metastasis
Resekcija ili radiofrekventna ablacija metastaze kolorektalnog karcinoma u jetri
Damir Jašaroviü, Dragoš Stojanoviü, Nebojša Mitroviü, Dejan Stevanoviü
Clinical Hospital Center Zemun, Belgrade, Serbia
Abstract
Background/Aim.  Liver resection is the treatment of
choice for solitary colorectal liver metastases in suitable
candidates. Recently, radiofrequency ablation (RFA) has be-
come a very popular procedure in the treatment of liver
metastases. The aim of this study was to compare outcomes
in patients with solitary colorectal liver metastasis who had
been subjected to resection or ablation. Methods. In this
retrospective study we analyzed and compared patients with
solitary colorectal liver metastases treated by resection or
ablation in the University Hospital Centre “Dr Dragiša Mi-
šoviý” in Belgrade from January 2002 until December 2009.
Results. In this study 94 (67.1%) patients underwent resec-
tion whereas 46 (32.9%) patients underwent RFA. Most of
the resected patients (59.6%) required major hepatectomy.
The median follow-up time was 28.4 months. Tumor abla-
tion was a significant predictor of the overall survival (p =
0.002; OR 3.75; 95% CI 1.696–8.284). Our study demon-
strated longer disease free-survival in the group of resected
patients compared to the RFA group (37.6 vs 22.3 months, p
= 0.073). The median overall survival was 56.3 months for
patients who underwent resection vs 25.1 months for those
in the RFA group (p = 0.005). Conclusion. This study
shows that the patients with solitary hepatic colorectal can-
cer metastases should be considered for hepatic resection
whenever it is feasible, because this procedure provides su-
perior long-term survival as compared to radiofrequency
ablation.
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Apstrakt
Uvod/Cilj. Hirurška resekcija jetre predstavlja metod iz-
bora u leÿenju pojedinaÿnih metastaza kolorektalnog kar-
cinoma u jetri kod odgovarajuýih bolesnika. Radiofrek-
ventna ablacija postaje sve popularnija metoda za leÿenje
metastaza u jetri. Cilj ove studije bio je da uporedi ishode
bolesti kod bolesnika sa pojedinaÿnom metastazom kolo-
rektalnog karcinoma u jetri koji su leÿeni hirurškom resek-
cijom u odnosu na bolesnike koji su leÿeni radiofrekvent-
nom ablacijom (RFA). Metode. U ovoj retrospektivnoj
studiji analizirani su bolesnici sa pojedinaÿnom metasta-
zom kolorektalnog karcinoma u jetri koji su leÿeni u KBC
„Dr Dragiša Mišoviý“ u Beogradu u periodu od januara
2002. do decembra 2009. godine. PoreĀeni su ishodi bole-
sti nakon hirurške resekcije jetre i nakon RFA metastaza u
jetri. Rezultati. Studijom je bilo obuhvaýeno 94 (67,1%)
bolesnika podvrgnutih resekciji jetre, dok je 46 (32,9%)
bolesnika leÿeno radiofrekventnom ablacijom. Kod veýine
bolesnika (59,6%) podvrgnutih hirurškoj resekciji uÿinjena
je major hepatektomija. Proseÿna dužina praýenja bolesnika
bila je 28,4 meseca. UtvrĀeno je da RFA tumora predstav-
lja znaÿajni prediktor dužine ukupnog preživljavanja (p =
0,002, OR 3,75, 95% CI 1,696–8,284), te da je duže preži-
vljavanje bez tegoba bilo u grupi bolesnika sa resekcijom u
poreĀenju sa RFA grupom (37,6 vs 22,3 meseca, p =
0,073). Proseÿno ukupno preživljavanje iznosilo je 56,3
meseca u grupi bolesnika sa hirurškom resekcijom naspram
25,1 mesec u RFA grupi (p = 0,005). Zakljuÿak. Kod od-
govarajuýih bolesnika sa pojedinaÿnom metastazom kolore-
ktalnog karcinoma u jetri trebalo bi razmotriti hiruršku rese-
kciju kad god je to izvodljivo, jer pruža duži period preživ-
ljavanja nego leÿenje radiofrekventnom ablacijom.
Kljuÿne reÿi:
kolorektalne neoplazme; hirurgija digestivnog sistema,
procedure; jetra, neoplazme; neoplazme, metastaze;
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Introduction
Colorectal cancer (CRC) remains one of the leading
causes of mortality caused by malignancy. Approximately
25% of all colorectal cancer patients at the time of initial di-
agnosis already have liver metastases, and additionally 50%
will develop distant metastases in the next 5 years 
1. Treat-
ment of colorectal cancer patients with metastases on the
liver is a therapeutic challenge and requires multidisciplinary
treatment. Nevertheless, surgery is the treatment of choice
for these patients. Survival data shows that with modern,
multidisciplinary treatment, 25–60% of patients with liver
resection to treat CRC metastases survive more than 5
years 
2–7.
 The goal of operation is to remove all metastatic
tumor tissue with acceptable resection margins. Some studies
show that narrow margins do not have influence on survival,
and that complete removal of metastases with minimal mar-
gins can be acceptable when it is not possible technically to
obtain wider margins
 8–10. Due to the importance of liver dis-
ease reduction in cases with metastases that cannot be re-
sected, new methods of local treatment of metastases are de-
veloped, among which is radiofrequency ablation (RFA).
RFA uses thermal energy produced by radiofrequency gen-
erator to destroy tumor and a small part of surrounding
healthy tissue 
1, 3, 4, 11. The five-year survival rate after RFA
in different studies ranges from 14% up to 27%
 1, 3, 5, 11–13.
Methods
The study is a retrospective analysis of patients with
solitary CRC liver metastases treated with RFA or surgical
resection, in the University Hospital Centre “Dr Dragiša Mi-
šoviü” in Belgrade, from January 2002 until December 2009.
Metastases are considered resectable when it is possible to
remove the tumor with negative resection margins, leaving
functionally sufficient liver tissue. The patients with extrahe-
patic metastases are excluded from this study. RFA was per-
formed with open approach after laparotomy to all patients in
this group, and the criteria for RFA were unresectability of
metastases and comorbidity (accompanying diseases and
conditions), which significantly increased the risk of liver re-
section. Data about chemotherapy were not known for all the
patients, and for most were not reliable, so these were not
considered in this study. The patients treated with RFA were
compared with the patients treated by liver resection by us-
ing t-test, Ȥ
2-test and Fisher’s exact test where appropriate.
Statistical analysis was performed by using JMP 4.0 and SPSS
version 16 software. Continuous variables were compared us-
ing Student’s t-test, and categorical variables were compared
by using Ȥ
2-test. The survival was plotted by Kaplan-Meier
method, and compared using the log-rank test. A value p <
0.05 was considered significant. The overall survival was cal-
culated from the moment of diagnosis until death. Cox regres-
sion method was used in order to establish independent pre-
dictors of disease outcome. Multivariate analysis was per-
formed with the Cox's proportional hazards model.
Results
A total of 140 patients with solitary CRC liver metasta-
ses were indentified from the database of operated patients in
the University Hospital Centre “Dr Dragiša Mišoviü” in Bel-
grade within the period from January 2002 until December
2009. The median follow-up time was 28.4 months. The me-
dian age of the patients was 62.9 years, among which were
74 (52.9%) male and 66 (47.1%) female patients.
Primary tumor localization was mostly on the left colon
and rectum, and most often localization was the sigmoid colon
with 32.9%, then cecum and ascending colon with 31.4%, the
rectum with 21.4%.  In 10% of the patients, primary localiza-
tion was unknown. Most of the patients had locally advanced
primary tumor, 72.9% with T3 stage, and 60% of the patients
had regional lymph nodes metastasis during the initial opera-
tion of the colon. Synchronous metastases in the liver were
seen in 66 (47.1%) of the patients (Table 1).
Liver metastases were resected in 94 (67.1%) of the pa-
tients, while in 46 (32.9%) of the patients RFA was per-
formed. The majority of resected patients (59.6%) underwent
major hepatectomy. The most often anatomic resection was
right hepatectomy (29.8%) then left hepatectomy (12.8%)
and extended right hepatectomy (12.8%). Extra-anatomic
“wedge” resections were represented with 12.8% (Table 2).
Table 1
Primary and metastatic tumors characteristics
 Tumor characteristics n %
Depth of primary tumor invasion
 T1 2 1.4
 T2 10 7.1
 T3 102 72.9
 T4 12 8.6
 unknown 14 10.0
Primary tumor localization
 cecum and ascending colon 44 31.4
 transverse colon 4 2.9
 descending colon 2 1.4
 sigmoid colon 46 32.9
 rectum 30 21.4
 unknown 14 10.0
Lymph node involvement (N1) 84 60.0
Synchronous primary tumor and metastasis 66 47.1Strana 544 VOJNOSANITETSKI PREGLED Volumen 71, Broj 6
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Most of the patients (89.4%) had R0 resection, with the me-
dian resection margin of 1.8 cm.
Table 2
Type of liver resection
 Type of resection n %
 Right hepatectomy 28 29.8
 Left hepatectomy 12 12.8
 Extended right hepatectomy 12 12.8
 Extended left hepatectomy 4 4.3
 Central liver resection 2 2.1
 Left lateral segmentectomy 10 10.6
 Right posterior segmentectomy 6 6.4
 Resection of one segment 8 8.5
 Wedge resection 12 12.8
Comparing the patients with RFA and those with resec-
tion showed no significant difference regarding sex (p =
0.632), age (p = 0.992) and lymph node involvement (p =
0.368) in these two groups. The patients in the resection group
had significantly larger metastases in the liver (5.5 cm in rela-
tion to 3.85 cm in the RFA group, p = 0.004) (Table 3).
The median disease free survival was 37.6 months for
the group of resected patients, and for the RFA group it
was 22.3 months (p = 0.073). The median overall survival
was 56.3 months for the resected patients, while for the
RFA group it was 25.1 months (p = 0.005). There were no
significant predictors of recurrence using univariate analy-
sis. Age, T-stage, N-stage, resection margins, size of me-
tastasis and RFA individually did not affect the recurrence
rate (Table 4).
Table 4
Local recurrence predictors
Factor Univariate p-value
RFA vs resection 0.07
Metastasis size 0.092
Lymph node involvement (N1) 0.20
Age 0.557
Gender 0.544
Tumor invasion (T-stage) 0.663
Primary tumor localization 0.910
Resection margin 0.569
RFA – radiofrequent ablation.
The significant difference regarding a shorter overall
survival period in the RFA group was established using mul-
tivariate analysis (p = 0.002; OR 3.75; 95% CI 1.696–8.284).
Age, T-stage, N-stage, resectional margin and size of metas-
tasis did not individually affect the overall survival period
(Table 5).
From the RFA group 16 (34.8%) patients developed lo-
cal intrahepatic recurrence. In 6 (13.0%) of the patients, re-
currence was on the ablation site or its margin. In the group
of resected patients, 12 (12.8%) patients developed local in-
trahepatic recurrence (p = 0.026). One of them had recur-
rence on the resection area. There were no significant differ-
ences in the occurrence of extrahepatic metastases between
the RFA and the resection group (21.7% and 18.9%, respec-
tively; p = 0.2).
There were no significant differences in the postopera-
tive complications rate (p = 0.35) between the two groups. In
the group of resected patients, 23 (48.9%) had complications
Table 3
Demographics and tumor characteristics of the patients
 Characteristics RFA Liver resection p-value
Gender (male), (%) 52.2 51.1 0.632
Age (years) 62.2  60.8  0.992
Size of liver metastases (cm) 3.8  5.5  0.004
Lymph node involvement (N1), (%) 52.17 63.83 0.368
Depth of primary tumor invasion
(T-stage) 0.11
 T1 0 2
 T2 2 8
 T3 34 68
 T4 4 8
unknown 6 8
Synchronous metastasis (%) 43.48 48.94 0.627
RFA – radiofrequent ablation.
Table 5
Overall survival predictors
Factor Univariate p value Hazard ratio 95% CI
RFA vs resection 0.006 2.5 1.3–4.8
Age 0.407
Gender 0.558
T stage 0.995
Primary tumor localization 0.946
Resection margin 0.330
Size of metastasis 0.975
Lymph node involvement (N1) 0.842
RFA – radiofrequent ablation; CI – Confidence interval.Volumen 71, Broj 6 VOJNOSANITETSKI PREGLED Strana 545
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of any kind, while in the RFA group, 18 (39.1%) of the pa-
tients had complications. Nevertheless, complications in the
RFA group were minor, mostly prolonged fever, while in the
group of resected patients major complications were regis-
tered. There was one (1.1%) postoperative death in the group
of resected patients. A patient with metastasis size 6 × 7 cm,
located between the right and the middle hepatic vein, un-
derwent extended right hepatectomy. Because of liver
bleeding, the patient was reoperated after 18 h, and adequate
hemostasis was accomplished. On the fourth postoperative
day the patient died from massive myocardial infarction. In
the RFA group, there was no postoperative mortality.
Discussion
Surgical resection of CRC liver metastases is not possi-
ble for many patients despite indisputable improvement of
surgical technique 
14, 15. The main limiting factors are anat-
omic localization of metastases, functionally insufficient
remnant liver, extensive comorbidity or the presence of ex-
trahepatic metastases 
16. Resection could not be performed in
cases of metastases invading the portal vein, hepatic artery or
the cava vein, or the portal vein thrombosis 
17. Several stud-
ies show that patients with unoperated liver metastases have
a low 5-year survival rate
 12, 15. Patients with CRC liver me-
tastases treated only with chemotherapy have poor prognosis
with the approximate median survival of 21 months, despite
its enormous improvement
 2.  The most usual cause of death
is the progression of liver illness, leading to liver insuffi-
ciency.
Some patients are not ideal candidates for the liver
solitary metastases resection, even though that is the method
of choice. Furthermore, the incidence and severity of com-
plications after RFA are more acceptable to surgeons than
those after resection of the liver. These factors have, among
others, increased popularity of RFA in treatment of liver
metastases. Despite its attractiveness, RFA can give worse
results than resection to patients that could be operated
 3.
We tried to establish if there is a significant difference
in the outcome for patients with solitary CRC liver metasta-
ses, treated by resection or RFA. Our data show that resec-
tion of the liver is superior to RFA. Therefore, we believe
that resection of CRC liver metastases remains the method of
choice for solitary lesions on the liver. Due to patients who
are not suitable candidates for hepatectomy, new “less inva-
sive” methods for treatment of liver metastases are pro-
moted. One of the most popular methods is thermal ablation
of metastases using radiofrequency power.  During previous
few years, RFA was suggested as alternative for surgical re-
section for patients with CRC metastases on the liver. In
2003, Oshowo et al. 
4 published that the 3-year survival was
55% for patients with solitary metastases in the liver that
were resected, while in the group where solitary metastases
were treated by RFA, survival was 53%. In that study, RFA
was used only for patients considered unsuitable for surgical
resection. This selection was made in our study as well, be-
cause surgical opinion in our hospital is that CRC liver me-
tastasis resection has to be done whenever it is possible, and
RFA is reserved for patients with non-resectable metastases,
or have other severe accompanying diseases that signifi-
cantly increase the risk concerning extensiveness of liver
surgery.
Our study showed a longer disease free survival in the
group of resected patients comparing to the RFA group (37.6
vs 22.3 months, respectively; p = 0.073). Many factors are
related with higher risk of recurrence after treatment of CRC
metastases in the liver. Most commonly described factor is
the size of metastases. In our study, the size of metastases
was significantly larger in the group of resected patients than
in the RFA group. A recent study has shown that the inci-
dence of local recurrence increases by 33% after RFA of
metastases larger than 3 cm
 2. Aloia et al. 
5 have analyzed
patients with solitary colorectal metastases in the liver and
compared patterns of local recurrence after hepatectomy and
RFA. They have established that RFA was associated with
the high (37%) incidence of local recurrence, unrelated to the
size of metastases, and with shorter disease-free survival and
survival period. Our study showed a significantly higher in-
cidence of local recurrence in the group of patients with RFA
(34.8%), compared to the resection group (12.8%). A recur-
rence rate after RFA in our study was similar to those pub-
lished in recent studies
 5, 11. Unfortunately, repeated treatment
of local recurrence with RFA is often impossible or unsuc-
cessful 
12, 18. That is the reason why we believe that resection
of the liver should be offered to all patients with resectable
CRC liver metastases.
We found no significant differences between the two
groups of patients in characteristics of primary tumor, in-
cluding depth of tumor invasion (T-stage), involvement of
lymph nodes (N-stage) or synchronicity of metastases. De-
spite similarities between the two groups in traditional pre-
dictors of survival, liver resection showed significantly better
results. The only statistically significant predictor of the
overall survival was the type of treatment (resection or
RFA). The differences in the disease-free survival and the
overall survival between the resected and RFA patients can-
not be explained by differences in demographic characteris-
tics, characteristics of primary tumor, characteristics of me-
tastases or other perioperative factors. That proves oncologi-
cal superiority of resection comparing to RFA.
Abdalla et al. 
3 have published a retrospective analysis
of patients with CRC liver metastases submitted to resec-
tion, RFA or a combination of these two methods. They
have shown a 4-year survival of 65% in the group of re-
sected patients, while in the RFA group it was 22%. Inter-
esting fact is that this percent in the group of patients sub-
mitted to both resection and RFA was only 36%. These
data show that RFA individually, or in combination with
resection, does not provide the length of survival compara-
ble with that after resection of the liver in treatment of
CRC liver metastases. RFA was used in treatment of soli-
tary metastases localized on the places impossible to leave
a negative resection margin. In their study, there is a statis-
tically significant difference in survival between patients
submitted to resection and those submitted to RFA (p =
0.025)
 3.  These data support our results that the medianStrana 546 VOJNOSANITETSKI PREGLED Volumen 71, Broj 6
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survival of the patients in the resection group is signifi-
cantly longer than in group treated with RFA.
There are certain limitations of our study.  Firstly, this
is a retrospective study with some unknown data. Secondly,
resection was done to our patients wherever it was possible,
leaving RFA for unresectable metastases or for those with
seriously damaged health by comorbidities. It is possible that
those factors contributed to the difference in the duration of
survival. Finally, not all the patients in this study were
treated by chemotherapy, and those who were did not receive
identical protocols, and we did not have data about chemo-
therapy of a certain number of patients. Therefore, the con-
clusions of this study should be interpreted with some cau-
tion.
Conclusion
Patients with solitary CRC liver metastases should be
considered for surgical liver resection whenever it is feasible,
because it provides a long-term survival compared to treat-
ment with radiofrequency ablation. This study promotes ag-
gressive resection of solitary liver metastases, because RFA
is associated with a shorter disease free-survival and a
shorter overall survival.
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